Currently in the United Kingdom, cardiovascular disease (CVD) risk assessment is based on the QRISK3 score, with a benchmark of 10% for 10-year CVD risk determining clinical intervention. Yet, effects on clinical practice are limited and the barriers call for a simple, non-invasive risk stratification tool. Retinal photography is becoming increasingly acceptable as a non-invasive imaging tool for CVD. Previously, we developed a novel CVD risk stratification system based on retinal photographs predicting future CVD risk. This study aimed to further validate our biomarker, Reti-CVD, 1) to detect risk group of \u226510% in 10-year CVD risk and 2) enhance risk assessment in individuals with QRISK3 of 7.5%-10% (termed as borderline-QRISK3 group) using the UK Biobank.<\/p>\n\n\n\n
RetiCVD scores were calculated and stratified into three risk groups based on optimized cut-off values from the UK Biobank. We used Cox proportional-hazards models to evaluate the ability of RetiCVD to predict CVD events in the general population. C-statistics was used to assess the prognostic value of adding RetiCVD to QRISK3 in borderline-QRISK3 group and three vulnerable subgroups.<\/p>\n\n\n\n
Among 45,233 participants with no history of CVD, 6.7% had CVD events during the 11-year follow-up. RetiCVD was associated with an increased risk of CVD (adjusted hazard ratio [HR] 1.34 (95% confidence interval [CI], 1.26-1.42) with a 14.7% (95% CI, 13.6-15.9%) 10-year CVD risk in RetiCVD-high-risk group. The 10-year CVD risk of the borderline-QRISK3 group was greater than 10% in RetiCVD-high-risk group (12.8% in non-statin cohort [n=16240], 11.5% in stage 1 hypertension cohort [n=5102], and 14.9% in middle-aged cohort [n=11,474]). C statistics increased by 0.013 (0.010-0.017) in non-statin cohort, 0.017 (0.010-0.024) in stage 1 hypertension cohort, and 0.022 (0.017-0.027) in middle-aged cohort for CVD event prediction after adding RetiCVD to QRISK3.<\/p>\n\n\n\n
RetiCVD has the potential to identify individuals with \u226510% 10-year CVD risk who are likely to benefit from earlier, upstream preventative CVD interventions. For borderline-QRISK3 individuals, RetiCVD could be used as a risk enhancer tool to help improve discernment accuracy, especially in early vulnerable adult groups.<\/p>\n","protected":false},"template":"","publication_type_categories":[12],"publication_categories":[16],"class_list":["post-1019","publication","type-publication","status-publish","hentry"],"acf":[],"_links":{"self":[{"href":"https:\/\/mediwhale.stage.studio-jt.co.kr\/ko\/wp-json\/wp\/v2\/publication\/1019","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/mediwhale.stage.studio-jt.co.kr\/ko\/wp-json\/wp\/v2\/publication"}],"about":[{"href":"https:\/\/mediwhale.stage.studio-jt.co.kr\/ko\/wp-json\/wp\/v2\/types\/publication"}],"version-history":[{"count":1,"href":"https:\/\/mediwhale.stage.studio-jt.co.kr\/ko\/wp-json\/wp\/v2\/publication\/1019\/revisions"}],"predecessor-version":[{"id":1020,"href":"https:\/\/mediwhale.stage.studio-jt.co.kr\/ko\/wp-json\/wp\/v2\/publication\/1019\/revisions\/1020"}],"wp:attachment":[{"href":"https:\/\/mediwhale.stage.studio-jt.co.kr\/ko\/wp-json\/wp\/v2\/media?parent=1019"}],"wp:term":[{"taxonomy":"publication_type_categories","embeddable":true,"href":"https:\/\/mediwhale.stage.studio-jt.co.kr\/ko\/wp-json\/wp\/v2\/publication_type_categories?post=1019"},{"taxonomy":"publication_categories","embeddable":true,"href":"https:\/\/mediwhale.stage.studio-jt.co.kr\/ko\/wp-json\/wp\/v2\/publication_categories?post=1019"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}